By every standard I can think of, I am overexposed to INCY. My other holdings would have to do awfully well before I could add to the position.
Y'know, the nice progress in the actual business isn't the biggest issue here. Nine months ago, management flubbed in public when they were called on lowballing and when they were asked directly to comment on leaked data. Today their response to a charge of lowballing was "That's the only arithmetic we're going to release," (excellent) and they seemed almost anxious to be confronted with a leak. It's the nature of surprises that they're...you know. At least they were prepared for the predictable this CC. The next time management are really cought by surprise in public, we can expect a disproportionate price reaction to how well they respond.
Thanks for the response, jacosa; as you are one of(if not THE) best poster on a Board desperately in need of informed posters.
I am like you. I already have a large position. The actual business looked good. I think additional label use is coming. Patience. Europe reimbursement concerns an issue? I don't know how to read into that. Seems like INCY is expecting to get their royalties. So, everything looks okay to really good.
Any info or thoughts you may have on the rheumatoid candidate now in Phase 3, I would be very interested to hear, jacosa.
Yes, nine months ago they sure did flub the Conference Call. However, there has since been some Management change. And I would like to think they have their 'act' together and feel as though they are on more solid footing when talking about Jakafi....